Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
about
Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertensionRedox biology in pulmonary arterial hypertension (2013 Grover Conference Series)The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension.Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension.Development of macitentan for the treatment of pulmonary arterial hypertension.Management of patients with pulmonary arterial hypertension due to congenital heart disease: recent advances and future directions.Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class.Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).Pharmacological treatment of HIV-associated pulmonary hypertension.Update on pulmonary arterial hypertension pharmacotherapy.Macitentan: A Review in Pulmonary Arterial Hypertension.Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes.Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.Lack of Pharmacokinetic Interactions Between Macitentan and a Combined Oral Contraceptive in Healthy Female Subjects.Self-reported physician practices in pulmonary arterial hypertension: Diagnosis, assessment, and referral.Pulmonary Arterial Hypertension in Women.Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
P2860
Q26747812-A73ADE03-563E-4B1F-AA58-E22424D52C6AQ26772286-2E09B0B0-636A-4F80-9536-F90BD22954FDQ33788447-1A2F9E03-FD9B-4AFB-8324-C52549BC74A0Q38559413-F1CC9A10-8B23-4885-AE25-46321EF995F2Q38570060-8873F98D-D61E-460C-891D-60952DCBA265Q38608883-D0E38A85-AC98-48AE-8D80-EF4080D3CAD8Q38649625-EA91B0ED-7FE9-4735-A226-7B948F388A9EQ38721897-DFC97D3F-147E-454C-B9E3-8E10F40223BDQ38728500-76DED501-A6F5-4F8E-B7E5-D298BC234B61Q38846020-1EFD85AF-19BE-4C5A-B3C9-361755BD2456Q38942648-0EB20372-5372-4392-BC2B-C6E2AF2305E7Q47102317-7C77B848-6816-42A4-B362-89CB9C8F2BAEQ47245549-11FF4E83-5B62-4FE2-86C6-DAC71A2C08F5Q50982502-EF3A7564-47F8-4CB9-94CA-D424FFFE51C3Q54973153-89F16B76-E912-4318-924E-CADB4F48E26DQ55408049-FE262C5D-7D5E-4269-AFCF-A3BC3F1B928BQ57484162-66F94C80-C914-4FEA-B34D-CAD0C7E4F591
P2860
Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
@en
Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
@nl
type
label
Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
@en
Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
@nl
prefLabel
Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
@en
Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
@nl
P2093
P50
P1433
P1476
Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
@en
P2093
Adam Torbicki
B K S Sastry
Elke Hunsche
Franck-Olivier Le Brun
Gérald Simonneau
Lewis J Rubin
Marion Delcroix
Richard N Channick
Sanjay Mehta
Tomás Pulido
P356
10.1016/J.JCHF.2014.07.013
P577
2014-11-11T00:00:00Z